Valuation: Pulmatrix Inc

Market Cap 6.17M 5.4M 4.98M 4.59M 8.65M 594M 8.86M 59.44M 23.44M 291M 23.18M 22.67M 1B P/E 2024
-2.67x
P/E 2025 -1.58x
Enterprise Value 2.08M 1.82M 1.68M 1.55M 2.92M 201M 2.99M 20.07M 7.91M 98.28M 7.83M 7.66M 339M EV / Sales 2024
2.05x
EV / Sales 2025 -
Free-Float
99.23%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 2024-07-19
Director TitleAgeSince
Director/Board Member 58 2019-10-31
Director/Board Member 57 2020-06-22
Director/Board Member 55 2020-09-30
Change 5-day change 1-year change 3-year change Capi.($)
-8.33%+504.03% - - 6.17M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -3.33%-2.62%+40.54%+184.05% 25.95B
Weighted average by Cap. -2.80%-2.36%+39.55%+143.13%

Financials

2024 2025
Net sales 7.81M 6.83M 6.3M 5.81M 10.94M 751M 11.21M 75.17M 29.64M 368M 29.31M 28.67M 1.27B -
Net income -9.56M -8.36M -7.72M -7.11M -13.39M -920M -13.72M -92.05M -36.29M -451M -35.9M -35.11M -1.55B -5.16M -4.52M -4.17M -3.84M -7.23M -497M -7.41M -49.71M -19.6M -243M -19.38M -18.96M -838M
Net Debt -9.52M -8.33M -7.69M -7.08M -13.34M -917M -13.67M -91.69M -36.15M -449M -35.75M -34.97M -1.55B -4.09M -3.58M -3.3M -3.04M -5.73M -394M -5.87M -39.37M -15.52M -193M -15.35M -15.01M -664M
Logo Pulmatrix Inc
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Employees
-